MedPath

"Comparing 0.1% Ropivacaine and 0.0625% Bupivacaine, with fentanyl for labour pain relief"

Phase 1
Not yet recruiting
Conditions
Obstetrics,
Registration Number
CTRI/2019/05/019271
Lead Sponsor
G Ranganaayaki
Brief Summary

With the help of this study, we would like to identify the drug which is safe and long acting with less adverse effects to be used as a labour analgesia. I would like to implicate findings of this study so as to provide adequate analgesia during labour. We would like to compare between 0.1% Ropivacaine and 0.0625% Bupivacaine in releiving labour pain with less or no adverse effects, duration of action of each drug.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Female
Target Recruitment
40
Inclusion Criteria
  • Parturients requesting epidural analgesia in SMVMCH from May 2019 to September 2020 2.
  • Parturients of ASA physical status 1 and 2 3.Parturients in active labour with cervical dilation of more than 3 cm 4.
  • Full term live fetus without any obstetric complication.
Exclusion Criteria
  • 1)Height < 150cm 2)BMI >30 3)Age <18 years 4)Anticipated difficult intubation 5)Contraindications for epidural catheter placement 6)Hyper-sensitivity to study drugs.
  • 7)Administration of IV analgesics within 1hr of epidural request.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Pain reliefVisual analog scale score will be recorded every 5 min for first 30 min, then at every 30 min till the end of labor. VAS at the end of the first stage and second stage is also noted.
Secondary Outcome Measures
NameTimeMethod
maternal sedationsensory blockade

Trial Locations

Locations (1)

Sri ManakulaVinayagar Medical College and Hospital

🇮🇳

Pondicherry, PONDICHERRY, India

Sri ManakulaVinayagar Medical College and Hospital
🇮🇳Pondicherry, PONDICHERRY, India
G Ranganaayaki
Principal investigator
9789709095
rangaganesan@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.